TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22480620
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A (BTX‐A) injections into plantar flexor muscles
Study: 11804663
Drug: Ethanol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (40 g/day) for 4 weeks
Study: 7487127
Drug: Azasetron (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azasetron (10 mg/day)
Study: 2148146
Drug: Low-oestrogen combined
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-oestrogen combined pill
Study: 28166190
Drug: Whole Stribild
Normalized name: Stribild
DrugBank: Elvitegravir (DB09101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Whole Stribild tablet with breakfast (reference)
Study: 23547240
Drug: Nebivolol (5-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol (5-20 mg/d)
Study: 23547240
Drug: Metoprolol (100-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (100-300 mg/d)
Study: 21486442
Drug: Higher Relative
Normalized name: (2R*,3S)-rel-1,2,3,4-butanetetroltetranitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher Relative Total Dose Intensity (RTDI)
Study: 19222455
Drug: 5-ALA patch-PDT
Normalized name: 5-ALA
DrugBank: Aminolevulinic acid (DB00855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-ALA patch-PDT
Study: 7967349
Drug: Calcium channel
Normalized name: Calcium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium channel blocker (nifedipine) pretreatment
Study: 3302010
Drug: Sucralfate, 1g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate, 1g twice daily
Study: 23527868
Drug: Moderately intoxicating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderately intoxicating dose of alcohol (mean blood alcohol concentration = 0.076 g/dl)
Study: 18977646
Drug: Beclomethasone dipropionate/formoterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate/formoterol combination via single inhaler
Study: 18977646
Drug: Beclomethasone dipropionate/formoterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate/formoterol combination via separate inhalers
Study: 13678928
Drug: Insulin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin (10 IU)
Study: 11003253
Drug: Human ultralente
Normalized name: INSULIN HUMAN ULTRALENTE 100 UNIT/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human ultralente insulin injected at 17.00 h
Study: 11003253
Drug: Human ultralente
Normalized name: INSULIN HUMAN ULTRALENTE 100 UNIT/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human ultralente insulin injected at 22.00 h
Study: 11003253
Drug: Regular insulin
Normalized name: Regular insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular insulin injected before dinner
Study: 11003253
Drug: Human ultralente
Normalized name: INSULIN HUMAN ULTRALENTE 100 UNIT/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human ultralente insulin (in general)
Study: 6418897
Drug: Intravesical chemotherapy
Normalized name: Valrubicin Intravesical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical chemotherapy (thiotepa or VM26)
Study: 30888448
Drug: Conventional technique
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional technique with ST/G autograft
Study: 25822598
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (techniques chosen by surgeons)
Study: 25822598
Drug: Non-surgical treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical treatment (initial sling immobilization followed by active rehabilitation)
Study: 24023786
Drug: simvastatin 40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: simvastatin 40 mg and ezetimibe 10 mg combination
Study: 19002384
Drug: Vandetanib 100
Normalized name: vandetanib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vandetanib 100 mg plus mFOLFOX6
Study: 19002384
Drug: Vandetanib 300
Normalized name: vandetanib 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vandetanib 300 mg plus mFOLFOX6
Study: 17255230
Drug: Allopurinol (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (900 mg/d)
Study: 15599989
Drug: Moderately active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderately active topical corticosteroids
Study: 11740820
Drug: Neovastat in
Normalized name: Neovastat
DrugBank: Neovastat (DB05387)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neovastat in addition to induction chemotherapy/radiotherapy
Study: 11740820
Drug: Neovastat as
Normalized name: Neovastat
DrugBank: Neovastat (DB05387)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neovastat as a monotherapy
Study: 7620239
Drug: Adrenaline (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenaline (5 mg)
Study: 2836651
Drug: hCRF (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: hCRF (2 micrograms/kg body weight) with naloxone (1.6 mg i.v. bolus, followed by an infusion at a rate of 1.2 mg/h)
Study: 29847831
Drug: Antidepressant pharmacotherapy
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant pharmacotherapy
Study: 29847831
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (CBASP + pharmacotherapy)
Study: 29847831
Drug: Monotherapy (either
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (either CBASP or pharmacotherapy)
Study: 16549259
Drug: Headache Impact
Approvals — FDA: no, EMA: no, PMDA: no
Description: Headache Impact Test (HIT) administered at baseline and 6-week follow-up
Study: 14596323
Drug: Mg citrate
Normalized name: K-Mg Citrate
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mg citrate
Study: 14596323
Drug: Mg amino-acid
Normalized name: silk amino acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mg amino-acid chelate
Study: 14596323
Drug: Mg oxide
Normalized name: citric acid/Mg oxide/Na picosulfate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mg oxide
Study: 9715552
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily gentamicin regimen (4 mg/kg Q 24 h)
Study: 9715552
Drug: Conventional gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional gentamicin regimen (2.5 mg/kg Q 12 h)
Study: 8285548
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml of 0.25% bupivacaine
Study: 8285548
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml of saline
Study: 27367263
Drug: Treatment 'failures'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment 'failures' (heavy drinkers) in COMBINE
Study: 27367263
Drug: Treatment 'failures'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment 'failures' (heavy drinkers) in Project MATCH
Study: 27367263
Drug: Treatment 'successes'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment 'successes' (non-heavy drinkers)
Study: 26042037
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg cocoa supplementation (acute)
Study: 26042037
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg cocoa supplementation (sub-chronic)
Study: 23816723
Drug: Fosinopril (5-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosinopril (5-40 mg/day)
Study: 23816723
Drug: Dioscorea bulbifera
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dioscorea bulbifera (500 mg BD)
Study: 18720882
Drug: Oral dexamethasone
Normalized name: dexamethasone Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dexamethasone combined with conventional methods
Study: 18720882
Drug: Intravenous dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous dexamethasone injection combined with conventional methods
Study: 18720882
Drug: Intratympanic dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intratympanic dexamethasone injection via external ear combined with conventional methods
Study: 18720882
Drug: Intratympanic dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intratympanic dexamethasone injection via pharyngotympanic tube combined with conventional methods
Study: 16051416
Drug: Propranolol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (2 mg or 4 mg i.v.) combined with oxytocin
Study: 11093393
Drug: Ibuprofen 400
Normalized name: ibuprofen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 400 mg three times daily for five days
Study: 11093393
Drug: Paracetamol 500
Normalized name: Paracetamol 500 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 500 mg with codeine 30 mg six hourly for 5 days
Study: 3957487
Drug: Deriphyllin-Digoxin tablets
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Deriphyllin-Digoxin tablets
Study: 15661109
Drug: Caffeine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (3 mg/kg bodyweight)
Study: 10232640
Drug: Transgalactooligosaccharides 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transgalactooligosaccharides 15 g/d
Study: 10232640
Drug: Transgalactooligosaccharides 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transgalactooligosaccharides 7.5 g/d
Study: 30507211
Drug: Culturally accommodated
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culturally accommodated treatment (A-CBT)
Study: 30507211
Drug: Standard group-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard group-based cognitive-behavioral treatment (S-CBT)
Study: 24008122
Drug: Aliskiren/amlodipine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren/amlodipine combination therapy (150mg aliskiren + 5mg amlodipine for 8 weeks, then 300mg aliskiren + 5mg amlodipine for another 8 weeks)
Study: 24008122
Drug: High-dose amlodipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose amlodipine monotherapy (10mg amlodipine for 16 weeks)
Study: 20036363
Drug: Atorvastatin 20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20 mg/day (early intensive lipid-lowering therapy)
Study: 11845337
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (soft cervical collar)
Study: 10430396
Drug: Eradication therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eradication therapy (Pantoprazole 40 mg daily, Amoxycilline 1000 mg b.i.d., Clarithromycine 500 mg b.i.d.)
Study: 6110818
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine given one month after hepatitis B immune globulin injection
Study: 6110818
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine and immune globulin given simultaneously
Study: 6110818
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine given alone
Study: 24289099
Drug: Internet-based guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based guided self-help treatment
Study: 18753119
Drug: Interviewer-administered questionnaire
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interviewer-administered questionnaire (IAQ)
Study: 17402320
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin therapy targeting glucose at 110‐140 mg/dl
Study: 17402320
Drug: Conventional insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional insulin therapy controlling glucose at 140‐200 mg/dl when exceeding 200 mg/dl
Study: 11210405
Drug: Fluoxetine 60
Normalized name: fluoxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 60 mg daily for 8 days + Almotriptan 12.5 mg on Day 8
Study: 11210405
Drug: Almotriptan 12.5
Normalized name: almotriptan 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almotriptan 12.5 mg on Day 8
Study: 10194994
Drug: Paracetamol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (20 mg/kg)
Study: 31738228
Drug: Nortriptyline +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nortriptyline + Morphine combination therapy
Study: 26879587
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (20 IU twice daily)
Study: 26162657
Drug: Short-term therapies
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term therapies (SPP and SFT)
Study: 23451806
Drug: Once-daily prolonged-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily prolonged-release mesalazine (4 g/day)
Study: 23451806
Drug: Twice-daily prolonged-release
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily prolonged-release mesalazine (4 g/day)
Study: 18405442
Drug: Targeted agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted agents targeting the hypoxia inducible factor-alfa (HIF-) / vascular endothelial growth factor (VEGF) pathway and mammalian target of rapamycin (mTOR) signal transduction pathway
Study: 15273470
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) 0.05 mg/kg/day for 1 year
Study: 2965154
Drug: rIFN alpha
Normalized name: rIFN-alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rIFN alpha 2C (2MU) given subcutaneously 5 times per week for 8-12 weeks, then once weekly until week 48.
Study: 2965154
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy of rIFN alpha 2C (2MU) and medroxyprogesterone acetate (MPA) 750 mg p.o. daily until week 48.
Study: 2965154
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group not explicitly mentioned, but both treatment groups had a median survival of 7 months.
Study: 26477350
Drug: MRI-specific play
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRI-specific play therapy intervention
Study: 24594090
Drug: i-gel supraglottic
Normalized name: iobenguane I-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: i-gel supraglottic airway (IG-SGA)
Study: 22744207
Drug: Outpatient long-term
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Outpatient long-term treatment
Study: 20412877
Drug: Intradermal vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal vaccination (0.2 ml, 6 microg HA per strain, split into two-site injections)
Study: 20412877
Drug: Intramuscular vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular vaccination (0.5 ml, 15 microg HA per strain)
Study: 12235694
Drug: 12 months
Normalized name: Elecare HMO 0-12 Months
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 months after cessation of chemotherapy
Study: 10421395
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition plus chemotherapy
Study: 2160490
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplementation (15 capsules of 1 g fish oil daily)
Study: 2160490
Drug: Olive oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil control (15 capsules of 1 g olive oil daily)
Study: 433814
Drug: Pure ethanol
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pure ethanol (9.3% w/v aqueous solution)
Study: 19860612
Drug: Weekly methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Weekly methotrexate (MTX) and daily 6-mercaptopurine maintenance therapy
Study: 18092436
Drug: Intranasal Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal Midazolam 0.2 mg/kg
Study: 18092436
Drug: Intranasal Ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal Ketamine 5 mg/kg
Study: 7857503
Drug: Hypericum extract
Normalized name: Hypericum extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypericum extract (3 x 300 mg)
Study: 7857503
Drug: Maprotiline (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maprotiline (3 x 25 mg)
Study: 870015
Drug: Intracameral injection
Normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intracameral injection of 50 microng of gentamicin
Study: 870015
Drug: Systemic and
Normalized name: Estradiol and Levonorgestrel Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic and topical chloramphenicol prophylaxis (historical control)
Study: 31856835
Drug: Doorstep provision
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doorstep provision of oral contraceptive pills and condoms
Study: 9477042
Drug: Daflon 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daflon 500 mg (2 tab/day)
Study: 3060511
Drug: Topical glucocorticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical glucocorticosteroids (budesonide, 100 micrograms in each nasal cavity every 12 hours)
Study: 28459795
Drug: Nordic hamstring
Normalized name: modified Vaccinia Ankara-Bavarian Nordic Injection [Jynneos]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nordic hamstring exercise (NHE) program, 4 weeks, twice a week, 3 sets of 6-10 repetitions
Study: 28628003
Drug: FCM-miniR (fludarabine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: FCM-miniR (fludarabine, cyclophosphamide, mitoxantrone, and low-dose rituximab)
Study: 16735174
Drug: Metabolite ratio
Normalized name: Terfenadine acid metabolite
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metabolite ratio (citrate/(choline+creatine)) and ADC values in patients with PSA >20 ng/ml (Group II)
Study: 16735174
Drug: Metabolite ratio
Normalized name: Terfenadine acid metabolite
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metabolite ratio and ADC values in patients with PSA 4-20 ng/ml (Group III)
Study: 8626878
Drug: Low-dose amlodipine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose amlodipine 2.5 mg daily
Study: 8626878
Drug: Low-dose benazepril
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose benazepril 10 mg daily
Study: 8626878
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of amlodipine 2.5 mg and benazepril 10 mg daily
Study: 30642308
Drug: Early medication
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early medication change (EMC) strategy with immediate switch to high doses of venlafaxine XR
Study: 30642308
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU) with continued escitalopram until day 28
Study: 28545804
Drug: Fluticasone Furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone Furoate (FF) 50 µg once daily in the evening
Study: 28545804
Drug: Fluticasone Furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone Furoate (FF) 50 µg
Study: 23712210
Drug: CBT-ERT (Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBT-ERT (Cognitive Behavioral Therapy enriched with Emotion Regulation Training)
Study: 18955525
Drug: OPT-80 50
Normalized name: Glau-Opt
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPT-80 50 mg
Study: 18955525
Drug: OPT-80 100
Normalized name: Glau-Opt
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPT-80 100 mg
Study: 18955525
Drug: OPT-80 200
Normalized name: Glau-Opt
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPT-80 200 mg
Study: 8174716
Drug: Leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide acetate (LA) plus oral contraceptive (OC) containing cyproterone acetate
Study: 20627691
Drug: Standardized monofilament
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized monofilament 10 g (pressure)
Study: 16723364
Drug: Ofloxacin plus
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ofloxacin plus metronidazole (ofloxacin 400 mg twice daily + metronidazole 500 mg twice daily)
Study: 8971305
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg/day plus azithromycin 500 mg/day for 3 days
Study: 8971305
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg/day plus azithromycin 500 mg/day for 3 days plus metronidazole 250 mg q.d.s. for 7 days
Study: 8971305
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg/day plus azithromycin 500 mg/day for 3 days plus metronidazole 250 q.d.s. for 7 days
Study: 8971305
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg/day plus clarithromycin 250 b.d. for 7 days
Study: 8971305
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg/day plus clarithromycin 250 b.d. for 7 days plus metronidazole 250 q.d.s. for 7 days
Study: 8971305
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg/day plus clarithromycin 250 mg b.d. for 7 days plus metronidazole 250 mg q.d.s. for 7 days
Study: 1595789
Drug: Buserelin acetate
Normalized name: buserelin acetate
DrugBank: Buserelin (DB06719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buserelin acetate (400 micrograms intranasal three times daily for 6 months)